Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial. (nature.com)

Authors: Hsiehchen D … Zhu H Journal: Nature Communications Published: 2026-07-21 DOI: https://doi.org/10.1038/s41467-026-75554-z